Ashique Rafique
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashique Rafique has a total of 244 co-authors. Here are the top co-authors by number of shared publications:
- William Olson
Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
49 shared publications - Christopher Daly
Regeneron Pharmaceuticals, Inc., Tarrytown, New York
48 shared publications - Drew Dudgeon
Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
48 shared publications - Erica Ullman
Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
48 shared publications - Pamela Krueger
Regeneron Pharmaceuticals, Inc., Tarrytown, New York
47 shared publications - Tammy Huang
Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
47 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Springer Nature in Research Square
Antagonist antibody to NPR1, REGN-NPR17544 (baloncibart), increases blood pressure and plasma volume
Hypotension and hypovolemia cause morbidity across many clinical disorders, yet pharmacologic options are limited. REGN-NPR1 7544 (REGN7544/baloncibart), a first-in-class monoclonal antibody, allosterically antagonizes natriuretic peptide receptor 1 (NPR1), a membrane guanylyl cyclase activated by atrial natriuretic peptide (ANP) and brain natriuretic peptide to promote vasorelaxation and natriuresis. REGN-NPR1 7544 bound human and cynomolgus monkey NPR1 with nanomolar affinity, increased systolic blood pressure (SBP) in NPR1 Hu/Hu mice by 10–15 mmHg for up to 28 days, corrected severe hypotension in ANP-overexpressing mice, and inhibited ANP-induced mesenteric vessel relaxation. In monkeys, SBP increased by 15–20 mmHg, with biomarkers consistent with plasma volume expansion. In a randomized, placebo-controlled, phase 1 single-ascending-dose study in healthy adults (N = 80), doses ≥ 100 mg were generally well-tolerated, producing sustained 5–10 mmHg SBP increases and biomarker signals consistent with volume expansion. These data implicate tonic NPR1 signaling in human blood pressure and volume regulation, supporting REGN-NPR1 7544 as a candidate for hypotension and hypovolemia.
- 18 November 2026
- Published by Springer Nature in Research Square
Open AccessAntagonist antibody to NPR1, REGN-NPR17544 (baloncibart), increases blood pressure and plasma volume
Hypotension and hypovolemia cause morbidity across many clinical disorders, yet pharmacologic options are limited. REGN-NPR1 7544 (REGN7544/baloncibart), a first-in-class monoclonal antibody, allosterically antagonizes natriuretic peptide receptor 1 (NPR1), a membrane guanylyl cyclase activated by atrial natriuretic peptide (ANP) and brain natriuretic peptide to promote vasorelaxation and natriuresis. REGN-NPR1 7544 bound human and cynomolgus monkey NPR1 with nanomolar affinity, increased systolic blood pressure (SBP) in NPR1 Hu/Hu mice by 10–15 mmHg for up to 28 days, corrected severe hypotension in ANP-overexpressing mice, and inhibited ANP-induced mesenteric vessel relaxation. In monkeys, SBP increased by 15–20 mmHg, with biomarkers consistent with plasma volume expansion. In a randomized, placebo-controlled, phase 1 single-ascending-dose study in healthy adults (N = 80), doses ≥ 100 mg were generally well-tolerated, producing sustained 5–10 mmHg SBP increases and biomarker signals consistent with volume expansion. These data implicate tonic NPR1 signaling in human blood pressure and volume regulation, supporting REGN-NPR1 7544 as a candidate for hypotension and hypovolemia.